Clinical Trials · NCT03972488

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Active Not RecruitingPhase 3Octreotide (Investigational)
Phase
Phase 3
Recruitment status
Active Not Recruiting
Sponsor
Advanced Accelerator Applications
Enrollment
226
Start date
Jan 2020
Locations
40 sites, 9 countries
Primary endpoint
Progression Free Survival (PFS) Per Central Assessment
View Octreotide compound reference